

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/68	A1	(11) International Publication Number: WO 99/05314 (43) International Publication Date: 4 February 1999 (04.02.99)
(21) International Application Number: PCT/GB98/02176 (22) International Filing Date: 21 July 1998 (21.07.98) (30) Priority Data: 9715522.0 24 July 1997 (24.07.97) GB (71) Applicant (for all designated States except US): ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): CALLAGHAN, Kay [GB/GB]; Gadbrook Park, Rudheath, Northwich, Cheshire CW9 7RA (GB). THEAKER, Jane [GB/GB]; Gadbrook Park, Rudheath, Northwich, Cheshire CW9 7RA (GB). (74) Agent: PHILLIPS, Neil, Godfrey, Alasdair, Zeneca Pharmaceuticals, Intellectual Property Dept., Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).		(81) Designated States: JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: USE OF 2'-O-METHYL RNA AS HYBRIDISATION PROBE (57) Abstract Digestion-resistant probes comprising 2'-O-methyl RNA for nucleic acid hybridisation assays. Their preparation and use.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

USE OF 2'-O-METHYL RNA AS HYBRIDISATION PROBE

This invention relates to improvements of the nucleic acid probes known as Molecular Beacons. Specifically, the use of modified nucleic acids for the synthesis of such probes has advantages in the detection of nucleic acid targets, in several applications including *in situ* hybridisation and homogeneous real time PCR assays.

Molecular Beacons are recently described nucleic acid probes that fluoresce upon hybridisation (Tyagi and Kramer, *Nature Biotechnology* 14: 303-308; 1996). The secondary structure of the probes is key and depends upon their sequence. Each probe has a target complementary portion (the loop) of about 15 or more nucleotides and additional sequences appended to each end that are complementary to each other. Finally, the probe has a fluorescent reporter molecule on one end and a fluorescence quencher at the other end. The self complementary end sequences can form stems by base pairing, thus bringing the fluorophore and quencher into close proximity and eliminating the fluorescence signal. However, in the presence of (loop) complementary target, the loop and target base pair and this "stretches out" the probe strand, thus removing the fluorophore from the quencher and allowing the reporter to fluoresce when illuminated appropriately. In this way, fluorescence is dependent upon hybridisation.

Molecular Beacons offers a number of advantages. It can be performed as a homogeneous assay. Because the "switching on" of the signal only occurs in the presence of target, there is no requirement to wash away excess unbound probe. This makes Molecular Beacons ideal for applications such as *in situ* hybridisation and real time PCR. It yields low background signals. In the absence of target and at an appropriate temperature, the probe self anneals and quenches fluorescence. When amplicon accumulates, some of the probe binds and is unwound, thereby generating fluorescence. In this way homogeneous (no wash, closed tube) fluorescence is produced and the low signals in the absence of target results in high ratios of signal to noise. It offers design flexibility. The use of standard stems allows rapid and reliable probe design. Furthermore, by correct design and optimisation of the stems, backgrounds at temperatures appropriate for PCR can be minimised.

For homogeneous analysis, the loop element of a Molecular Beacon should be thermodynamically favoured over the stem portion, but the stem should form readily at the

15
12
27

assay temperature. These key requirements make it likely that long loops and stems are necessary, which has consequences for the synthesis yields and purity of Molecular Beacons. Furthermore, while long loops produce good separations between fluorophore and quencher, long stems melt over a broad temperature window leading to higher background signals and greater noise in those signals.

We have devised and now provide modified RNA probes which have a number of beneficial characteristics when used as Molecular Beacons.

Therefore in a first aspect of the present invention we provide a Molecular Beacons assay method using a 2'-O-substituted RNA probe having both a donor and a quencher species attached. The 2'-O-substituent is conveniently a methyl, propyl, butyl or allyl group. It is preferably a 2-methyl group.

The Molecular Beacons assay method is disclosed in WO-95/13399 (Public Health Research Institute of New York). This essentially comprises the detection of a pre-selected nucleic acid sequence by contacting a sample believed to contain said sequence with a Beacons probe under hybridisation conditions such that there is a detectable change in Beacons signal from the probe if the pre-selected sequence is present in the sample.

The Beacons probe is a unitary probe comprising a single stranded target complementary sequence, a stem duplex consisting of nucleotide sequences 5' and 3' to the target complement sequence and having a melting temperature lower than the target complementary sequence/target sequence melting temperature, and at least one label pair, each pair comprising a first label conjugated to the probe at or near the 5' terminus of the probe and a second label conjugated to the probe at or near the 3' terminus of the probe. Under assay conditions, hybridisation of the target complementary sequence to the target sequence leads to a change in Beacons signal from the label pair.

The donor and acceptor species are attached to the Molecular Beacons probe in any convenient way. By way of non-limiting example either species may be attached to the 3' terminus of the probe via controlled pore glass (CPG) based synthesis or attached to the 5' terminus via 5'-phosphoramidite chemistry. The donor and quencher species are attached at any convenient locations on the probes, such as for example at or near the ends of the probe, preferably at the ends of the probe. Examples of convenient donor species will be apparent to the scientist of ordinary skill and include FAM, TET, JOE, HEX, ROX, BODIPY and EDANS. Convenient acceptor species include TAMRA, Pyrene butyrate, and DABCYL.

Still further convenient details are found in, for example Livak et al, "PCR methods and applications, 1995, 4, 357-362; WO-95/13399 (Public Health Research Institute of New York).

Advantages of the 2'-O-substituted probes include a higher T_m when annealed to DNA target, relative to the "standard" DNA probes; this means that shorter probes can be designed to function at similar temperatures and therefore a higher level of specificity is possible - a single mismatch within a short oligonucleotide has a greater destabilising effect than when the same mismatch is in a larger hybridised region

Secondly 'traditional' Molecular Beacons perform optionally in magnesium concentrations of 3.5 mM or greater. With the new 2'-O-substituted Molecular Beacons significantly lower magnesium concentrations can be utilised. This has substantial benefits for the specificity of PCR and in particular ARMS reactions. [ARMS technology is described in, for example Newton et al., 1989, Nucleic Acids Research (17) 2503-2516].

Also, annealing of 2'-O-substituted RNA to complementary 2'-O-substituted RNA targets is even more favourable than to DNA targets; this permits a shorter stem region to be used which has particular benefits for the design of effective Beacon probes. This has three functional benefits for the use of Molecular Beacons, particularly in real time PCR systems.

Firstly, when a Molecular Beacon is cooled from high temperature (94°C) to low temperature (20°C) the fluorescence changes from high (Beacon is a random coil) to low (Beacon has adopted a stem/loop formation), see Figure 1. The temperature range of the transition from "random coil" to stem-loop structure depends upon the length of the stem sequence; longer sequences are expected to melt over a wider temperature window, possibly in a series of small steps, while shorter stems are more likely to undergo a single, rapid stem transition. This is important for the design of effective real time assays in which backgrounds should be as low as possible: the stem/loop structure should be fully formed at the temperature at which the fluorescence is measured and the probe/target interaction should also be favoured at this temperature.

Secondly, short stems have an additional advantage in that they should exhibit lower noise in positive hybridisations, due to their lower flexibility, and hence reduced ability to give a degree of fluorophore quenching.

Thirdly, at lower temperatures, the free stem sequences can "find" each other, even when the loop and the target have annealed. The hybridised duplex can be bent around and

thus quenching of the fluorescence signal can occur. The consequences of this feature also favour the design of Molecular Beacons with shorter loop portions to minimise this hybrid bending, since shorter duplexes are more physically constrained and cannot bend so easily into this closed formation

5 A still further advantage is that where true quantitation of PCR product is required, it is desirable to have no cleavage of dual labelled probes since the fluorescence observed in such reactions reflects the accumulation of the cleavage reactions through all the previous cycles, thus obscuring to some extent the true level of amplicon actually accumulated thus far. Many of the enzymes commonly used in PCR have an endogenous 5'-nuclease activity and
10 may cleave the probes.

 Therefore in a further aspect of the present invention we provide 2'-O-substituted RNA probes having both a donor and a quencher species attached. The 2'-O-substituent is conveniently a methyl, propyl, butyl or allyl group. It is preferably a 2-O-methyl group. These modified nucleic acids are nuclease resistant; this is important in assays where nucleases may
15 be present such as in situ hybridisation or in real time PCR assays.

 The invention further relates to diagnostic kits comprising one or more of the Beacons probes of the invention, together with appropriate buffers and other reagents, and instructions for use.

 The invention will now be illustrated but not limited by reference to the following
20 Example and Figures wherein:

Figure 1 shows cooling curves for 2-Methyl RNA Molecular Beacon 0007M, in the presence or absence of synthetic oligonucleotide target (R297). Fluorescence readings were taken throughout the cooling range and plotted against temperature. Raw fluorescence
25 intensity is along the Y-axis.

Figure 2 shows a similar series of curves in which PCR amplicons at various concentrations from neat to 1/8 diluted were cooled in the presence of Beacon 0007M. On the X-axis temperature decreases from 94°C to 11°C as before, but to permit accurate tube to tube comparisons, the data are equalised to a baseline between temperatures 84°C to 74°C where
30 each of the curves is flat. When the mixtures have cooled to below 50°C, the curves reach their minimum fluorescences and it is appropriate to compare them. The fluorescence value at this point rise with the quantity of target within the tube.

Figure 3 illustrates the increase in Beacon fluorescence monitored at the same point in every PCR cycle (the 60°C anneal step). Where template is included in the reaction, fluorescence increases above the background (shown by the no template control). This increase becomes significant at ~28 cycles.

5 **Figure 4** shows the same reactions using Beacon 0009M in place of the previous 0007M Beacon. The fluorescence grows smoothly with less background noise and reaches substantially larger values. This reflects the improved efficiency of this Beacon due to enhanced design.

10 **Figure 5** shows the detection of normal alleles (N mix) of the hereditary haemochromatosis mutations C282Y het and C282Y homo, together with wild type and control sequences

Figure 6 shows the detection of mutant alleles (M mix) of the hereditary haemochromatosis mutations C282Y het and C282Y homo, together with wild type and control sequences

15 **Figure 7** shows the detection of normal alleles (N mix) of the hereditary haemochromatosis mutation H63D, together with wild type and control sequences.

Figure 8 shows the detection of mutant alleles (M mix) of the hereditary haemochromatosis mutation H63D, together with wild type and control sequences.

Example 1

20 **Reagents:**

Primers and Probes

R351: CGC TGA TGA ATG TGA AAA ATC TAA

R352: AGA AGT TCC AGA TAT TGC CTG CTT

0007M (2-methylRNA Molecular Beacon): (FAM)-GCG AGC AAA AGA CCU AUU AGA
25 CAC AGA GAA GCU CGC-(Quencher); underlined portions indicate the self complementary stems.

R297: CTT TTG TTC TCT GTG TCT AAT AGG TCT TTT TCT GAA; synthetic target for Beacon 0007M, underlined region is the complementary portion.

- 6 -

Other Reagents:

10xARMS(35) Buffer: 100 mM Tris-HCl (pH 8.3 at 25°C), 500 mM KCl,
3.5 mM MgCl₂, 0.1% gelatin)

1 mM dNTPs: 1mM each dNTP diluted from

5 10mM stocks(Pharmacia)

Amplitaq Gold (5U/μl): from Perkin-Elmer

ROX standard: ROX conjugated oligonucleotide, 600 nM stock solution

Melt Characteristics:**Reaction Mix**

10 400 nM Molecular Beacon 0007M in 1xARMS (3.5) [diluted from 10-fold stock (10 x ARMS)] plus dNTPs at 100mM final, ROX standard at 60 nM and targets at various concentrations. Targets are either synthetic oligo target (R297) at 1μM or double stranded amplicon produced by PCR with primers R351 and R352 and serially diluted.

Cycling Parameters

15 94°C 2 min; then 84 steps of 15 seconds decreasing from 94°C to 11°C using an ABI PRISM system 7700, fluorescence readings monitored at each temperature.

Results

Figure 1 shows the results obtained with 0007M in the presence (◆) or absence (■) of target. The high fluorescences at elevated temperatures show the stem has not formed and the probe is essentially randomly coiled. As the temperature decreases, the fluorescence decreases in the “no target” reaction, while in the presence of excess target, an increase in fluorescence is observed, peaking at around 56°C. The subsequent reduction in this fluorescence reflects the high affinity of the stems for each other and at lower temperatures, the probe target duplex can be bent permitting stems to form and fluorescence to switch off.

25 Figure 2 shows a similar series of curves with varying quantities of double-stranded amplicon; a 2-fold serial dilution from “neat” to 1/16 and a negative control. The data have been equalised for fluorescence between 88°C and 74°C (where each line is flat) to allow direct comparison between tubes. There is a clear difference between positive and negative samples and the dilution series of target numbers is clearly reflected in the relative

fluorescences, particularly at lower temperatures. There are two further observations to be drawn from this data:

1. the larger amplicon target is less prone to subsequent bending and closure than the oligonucleotide target;
- 5 2. the target was heat denatured only once and it might have been expected that the "other" strand would displace the probe from its binding site. This was not the case since fluorescences remained substantial throughout the cooling.

Amplification Reactions:

Reaction Mix

- 10 1xARMS (3.5), buffer added to 100 μ M dNTPs, 500 nM each primer (R351, R352), 60 nM ROX standard, 400 nM Beacon 0007M, 2 Units Amplitaq Gold (per 50 μ l reaction), 5 μ l (50 ng) human genomic DNA.

Cycling Conditions

The reactions were cycled and fluorescence read using the conditions below.

- 15 94°C for 20 min to activate the Amplitaq Gold. Followed by 40 cycles of:
94°C for 41s, 60°C for 42 s, 72°C for 52 s. Fluorescence data was collected and analysed for the 60°C anneal step.

Results

The output from an amplification reaction as described above is shown in Figure 3.

- 20 There is a clear difference between positive and negative samples using this system. We anticipate that the probe design and reaction conditions may be further optimised, thus yielding increased fluorescences, whilst minimising the signal noise and enhancing the sensitivity of the technique.

Example 2

In this Example we disclose a further, improved Molecular Beacon. In this the loop portion of the probe was enlarged to ensure strong binding to target and good physical separation of fluorophore from quencher. In addition, the stem was decreased in size to a CGCG tetramer which has the multiple benefits of short length to minimise the folding back

- 8 -

of the bound duplex, high T_m due to its particular sequence composition, 5'-terminal C adjacent to the fluorophore which avoids possible quenching by the G, as present in probe 0007M.

The improved Beacon is 0009M: (FAM) - CGC GGA AAA ASA CCU AUU AGA
 5 CAC AGA GAA CAC GCG - (Quencher). Underlined portions are the stem. All bases are 2'-O-methyl RNA.

Example 3

10 Detection of Hereditary Haemochromatosis mutations using 2'-O-methyl RNA molecular beacons

1) C282Y ARMS Test

15 Materials and Methods

Two mixes were made up, the first (N) to detect the normal (wild type) allele and the second (M) to detect the mutant allele. The mixes differ only by the 3' base of the ARMS primer. Final concentrations of mix components are shown below:

20

C282Y N mix	C282Y M mix
1x Beacons buffer	1x Beacons buffer
100mM dNTPs	100mM dNTPs
1x Passive Reference (60nM ROX)	1x Passive Reference (60nM ROX)
0.5mM common forward primer (R279-97)	0.5mM common forward primer (R279-97)
0.5mM reverse ARMS normal primer (R280-97)	0.5mM reverse ARMS normal primer (R281-97)
0.4mM molecular beacon (0037M)	0.4mM molecular beacon (0037M)
1 unit AmpliTaq Gold enzyme	1 unit AmpliTaq Gold enzyme

Composition of 1x Beacons buffer:

50mM KCl

10mM Tris (pH 8.3)

25

- 9 -

3.5mM MgCl₂

0.01% (w/v) gelatin

Primer / Beacon Sequences (5' → 3'):

R279-97 AAGTGCCTCCTTTGGTGAAGCTGACACA5 **R280-97** TGATCCAGGCCTGGGTGCTCCACCTGAC**R281-97** TGATCCAGGCCTGGGTGCTCCACCTGAT**0037M** (FAM)-CGCGAGUUCGAACCUAAAGACGUAUUGCCCAACGCG-
(Quencher)

10 The mixes were dispensed into 20µl aliquots in optical tubes. 5µl of genomic DNA (prepared from blood by alkali lysis and diluted 1/5 in water) was added to duplicate aliquots of both mixes. Examples of wild type, heterozygous mutant and homozygous mutant samples were used.

The tubes were placed in a thermal cycler (Applied Biosystems 7700) and the
15 following PCR program was run:

20 minutes at 94°C followed by

20 cycles of

45 seconds at 94°C

45 seconds at 60°C

20 then 25 cycles of

45 seconds at 94°C

45 seconds at 40°C

The results are shown in Figure 5 and Figure 6

The results above demonstrate that the N mix only amplifies genomic DNA which
25 contains the wild type allele (solid diamonds and clear triangles) and the M mix only amplifies genomic DNA which contains the mutant allele (clear triangles and solid circles). Amplification does not occur in either mix in the absence of genomic DNA (Xs).

2) H63D ARMS Test30 **Materials and Methods**

Two mixes were made up, the first (N) to detect the normal (wild type) allele and the second (M) to detect the mutant allele. The mixes differ only by the 3' base of the ARMS

primer. All primers in the H63D test have the same 26mer non-homologous tail sequence at their 5'-end. Final concentrations of mix components are shown below:

H63D N mix	H63D M mix
1x Beacons buffer	1x Beacons buffer
100mM dNTPs	100mM dNTPs
1x Passive Reference (60nM ROX)	1x Passive Reference (60nM ROX)
0.5mM common forward primer (R369-98)	0.5mM common forward primer (R369-98)
0.5mM reverse ARMS normal primer (R370-99)	0.5mM reverse ARMS normal primer (R371-98)
0.4mM molecular beacon (MB026-98)	0.4mM molecular beacon (MB026-98)
1 unit AmpliTaq Gold enzyme	1 unit AmpliTaq Gold enzyme

5 Composition of 1x Beacons buffer

50mM KCl

10mM Tris (pH 8.3)

3.5mM MgCl₂

0.01% (w/v) gelatin

10 Primer / Beacon Sequences (5'→3')

R369-98

GCGTACTAGCGTACCACGTGTCGACTTCCTACTACACATGGTTAAGGCCTG

R370-98

GCGTACTAGCGTACCACGTGTCGACTGGGCTCCACACGGCGACTCTCAAG

15 **R371-98**

GCGTACTAGCGTACCACGTGTCGACTGGGCTCCACACGGCGACTCTCAAC

MB026-98 (FAM)-CGCGGGAUGACCAGCUGUUCGUGUUCUACGCG-(Quencher)

The mixes were dispensed into 20µl aliquots in optical tubes. 5µl of genomic DNA (prepared from blood using the Gentra PureGene kit and diluted in water to 10ng/µl) was added to duplicate aliquots of both mixes. Examples of wild type, heterozygous mutant and homozygous mutant samples were used.

20

- 11 -

The tubes were placed in a thermal cycler (Applied Biosystems 7700) and the following PCR program was run:

20 minutes at 94°C followed by

20 cycles of

5 45 seconds at 94°C

45 seconds at 60°C

then 25 cycles of

45 seconds at 94°C

45 seconds at 40°C

10

The results are shown in Figures 7 and 8.

Again, the results demonstrate that the N mix only amplifies genomic DNA containing the wild type allele (solid diamonds and clear triangles) and the M mix only amplifies genomic DNA containing the mutant allele (clear triangles and solid circles). Amplification
15 does not occur in either mix in the absence of genomic DNA (Xs).

The amplification protocol was identical to the run shown in Figure 3. The results from this amplification are shown in Figure 4.

-12-

SEQUENCE LISTING

(1) GENERAL INFORMATION:

5 (i) APPLICANT:

(A) NAME: Zeneca Limited

(B) STREET: 15 Stanhope Gate

(C) CITY: London

(D) STATE: England

10 (E) COUNTRY: United Kingdom

(F) POSTAL CODE (ZIP): W1Y 6LN

(G) TELEPHONE: 0171 304 5000

(H) TELEFAX: 0171 304 5151

(I) TELEX: 0171 304 2042

15

(ii) TITLE OF INVENTION: ASSAYS

(iii) NUMBER OF SEQUENCES: 13

20 (iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

25

(vi) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: GB 9715522.0

(B) FILING DATE: 24-JUL-1997

30

-13-

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 base pairs .

5 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

CGCTGATGAA TGTGAAAAAT CTAA

24

15

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 base pairs

20 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

AGAAGTTCCA GATATTGCCT GCTT

24

30

-14-

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GCGAGCAAAA GACCUAUUAG ACACAGAGAA GCUCGC

36

15

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

CTTTTGTTCT CTGTGTCTAA TAGGTCTTTT TCTGAA

36

30

-15-

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

CGCGGAAAAA ACCAAGACAC AGAGAACACG CG

32

15

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

AAGTGCCTCC TTTGGTGAAG CTGACACA

28

30

-16-

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 28 base pairs

5 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

TGATCCAGGC CTGGGTGCTC CACCTGAC

28

15

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 28 base pairs

20 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

TGATCCAGGC CTGGGTGCTC CACCTGAT

28

30

-17-

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 base pairs

5 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

CGCGAGUUCG AACCUAAAGA CGUAUUGCCC AACGCG

36

15

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 51 base pairs

20 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

GCGTACTAGC GTACCACGTG TCGACTTCCT ACTACACATG GTTAAGGCCT G

51

30

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 50 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

GCGTACTAGC GTACCACGTG TCGACTGGGC TCCACACGGC GACTCTCAAG

50

15

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 50 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

GCGTACTAGC GTACCACGTG TCGACTGGGC TCCACACGGC GACTCTCAAC

50

30

-19-

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- 10 (ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

CGCGGGAUGA CCAGCUGUUC GUGUUCUACG CG


32

CLAIMS:


We claim:

- 5 1. A nuclease resistant probe comprising 2'-O-substituted RNA and having donor and acceptor species attached at or near its termini.
2. A probe as claimed in claim 1 and further comprising a stem duplex consisting of nucleotide sequences 5' and 3' to a target complementary sequence.
- 10 3. A probe as claimed in claim 2 wherein the stem duplex is of 3-6 bases in length.
4. A probe as claimed in any one of claims 1-3 wherein the 2-O-substituent is an alkyl group.
- 15 5. A probe as claimed in claim 3 wherein the alkyl group is methyl.
6. A diagnostic assay which comprises the use of a probe as claimed in any one of the previous claims.
- 20 7. A diagnostic assay as claimed in claim 6 and being a real time assay.
8. A diagnostic kit comprising one or more probes as claimed in any one of the previous claims together with one or more of appropriate buffers, reagents and instructions for use.
- 25


1/8

Figure 1


2/8

Figure 2


3/8

Figure 3**Molecular beacon 0007M in Real time ARMS Reaction**

4/8

Figure 4

5/8

Figure 5**Amplification Plot for C282Y N mix**

6/8




Figure 6

Figure 7

8/8

Figure 8

INTERNATIONAL SEARCH REPORT

Interr. Application No
PCT/GB 98/02176

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	TYAGI S ET AL: "MOLECULAR BEACONS: PROBES THAT FLUORESCCE UPON HYBRIDIZATION" BIO/TECHNOLOGY, vol. 14, 1 March 1996, pages 303-308, XP000196024 cited in the application see the whole document	1-8
Y	WO 95 13399 A (PUBLIC HEALTH RESEARCH INST OF) 18 May 1995 cited in the application see the whole document	1-8
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier document but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
"&" document member of the same patent family

Date of the actual completion of the international search

4 November 1998

Date of mailing of the international search report

11/11/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hagenmaier, S

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 98/02176

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	HIDEO INOUE ET AL: "SYNTHESIS AND HYBRIDIZATION STUDIES ON TWO COMPLEMENTARY NONA(2'-O-METHYL)RIBONUCLEOTIDES" NUCLEIC ACIDS RESEARCH, vol. 15, no. 15, 11 August 1987, pages 6131-6148, XP000570336 see the whole document ---	1-8
Y	SUDHIR AGRAWAL: "ANTISENSE OLIGONUCLEOTIDES AS ANTIVIRAL AGENTS" TRENDS IN BIOTECHNOLOGY, vol. 10, no. 5, 1 May 1992, pages 152-158, XP000272382 see the whole document ---	1-8
A	UHLMANN E ET AL: "ANTISENSE OLIGONUCLEOTIDES: A NEW THERAPEUTIC PRINCIPLE" CHEMICAL REVIEWS, vol. 90, no. 4, 1 June 1990, pages 543-584, XP000141412 see the whole document ---	1-8
A	EP 0 144 914 A (MILES LAB) 19 June 1985 see the whole document -----	1-8

INTERNATIONAL SEARCH REPORT

information on patent family members

Inter. Regional Application No

PCT/GB 98/02176

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9513399 A	18-05-1995	AU 1292195 A	29-05-1995
		CA 2176348 A	18-05-1995
		EP 0728218 A	28-08-1996
		JP 9504950 T	20-05-1997

EP 0144914 A	19-06-1985	AU 578436 B	27-10-1988
		AU 3656084 A	20-06-1985
		AU 578641 B	03-11-1988
		AU 3656184 A	20-06-1985
		AU 579335 B	24-11-1988
		AU 3656284 A	20-06-1985
		AU 580745 B	02-02-1989
		AU 3656384 A	20-06-1985
		CA 1250230 A	21-02-1989
		CA 1239580 A	26-07-1988
		CA 1250232 A	21-02-1989
		CA 1238575 A	28-06-1988
		DK 591484 A	13-06-1985
		DK 591684 A	13-06-1985
		DK 591784 A,B,	13-06-1985
		DK 591984 A	13-06-1985
		EP 0144913 A	19-06-1985
		EP 0146039 A	26-06-1985
		EP 0146815 A	03-07-1985
		FI 844866 A,B	13-06-1985
		FI 844867 A	13-06-1985
		FI 844868 A	13-06-1985
		FI 844869 A	13-06-1985
		JP 1829406 C	15-03-1994
		JP 5031108 B	11-05-1993
		JP 60151559 A	09-08-1985
		JP 60201256 A	11-10-1985
		JP 60201257 A	11-10-1985
		JP 60179657 A	13-09-1985
		US 4563417 A	07-01-1986

Form PCT/ISA210 (patent family annex) (July 1992)